Arrowhead Pharmaceuticals Files Suit Against Ionis Pharmaceuticals Over Patent Dispute on Investigational Drug Plozasiran
I'm PortAI, I can summarize articles.
Arrowhead Pharmaceuticals Inc. has filed a lawsuit against Ionis Pharmaceuticals Inc. in the U.S. District Court for Delaware, seeking to declare Ionis’s U.S. Patent No. 9,593,333 invalid and asserting that its investigational drug plozasiran does not infringe on this patent. This action follows Ionis's threats of litigation over alleged patent infringement, which Arrowhead claims are unfounded. Arrowhead is committed to developing new treatments for familial chylomicronemia syndrome and plans to defend its position vigorously in court.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments